跳至主要内容
临床试验/ISRCTN78679862
ISRCTN78679862已完成1 期

Single-blind randomised controlled phase 1a trial of the safety and immunogenicity of lyophilised recombinant precipitated tropical malaria vaccine (BK-SE36) in Japan

The Research Foundation for Microbial Diseases of Osaka University (BIKEN) (Japan)0 个研究点目标入组 40 人开始时间: 2009年12月23日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

2010 results in https://pubmed.ncbi.nlm.nih.gov/20493274/ (added 29/12/2020)

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Healthy adult Japanese males aged 20 to 35 years (age on informed consent)
  • 2. Those whose body mass index (BMI) is 18.5 to 25.0 kg/m^2
  • 3. Those who are able to agree, comply with matters to be observed during participation in the trial, undergo consultation/examination, as described in this protocol, and report symptoms
  • 4. Those who are considered to be eligible to participate in this trial based on screening:
  • 4.1. Vital signs and physical examination are within baseline range
  • 4.2. Haematology: within 15% deviations from the upper and lower limits of the baseline range. The differential white blood count is not questioned when the white blood cell count is within the baseline range.
  • 4.3. Blood chemistry:
  • 4.3.1. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatinine within the baseline range
  • 4.3.2. Total bilirubin, triglyceride (TG) within 50% deviation from the upper limit
  • 4.3.3. Serum electrolytes within the baseline range
  • 4.3.4. Other blood chemistry items within 15% deviation from the upper and lower limits of the baseline range
  • 4.4. Urinalysis within the normal range
  • 4.5. Infectious disease tests within the normal ranges

排除标准

  • 1. Persons with fever (37.5°C or higher) on administration of the test vaccine
  • 2. Persons with clear symptoms of serious acute disorders
  • 3. Persons with a clear history of food/drug-related anaphylaxis
  • 4. Persons with a clear history of malaria, or those with anti-plasmodium falciparum (SE36 antigen) antibody
  • 5. Persons with a history or present illness of disorders requiring gastrointestinal surgery, serious cardiovascular/blood system/respiratory/liver/kidney/digestive tract/neuropsychiatric disorders, or developmental anomalies
  • 6. Persons with a history of fever within 2 days after preventive administration with other types of vaccine, or those in whom symptoms have suggested systemic allergy
  • 7. Persons with a history of convulsion
  • 8. Persons under a diagnosis of immunodeficiency
  • 9. Persons with a history or tentative diagnosis of drug allergy
  • 10. Persons with a history of or present drug/ alcohol dependency
  • 11. Persons who took any medication within 1 week before administration of this test vaccine
  • 12. Persons to whom any live vaccine was administered within 4 weeks before administration of this test vaccine, or inactivated vaccine/toxoid was administered within 1 week
  • 13. Persons who participated in another trial within 4 months before administration of this test vaccine
  • 14. Persons in whom 200 ml of blood was collected (donation) within 1 month before administration of this test vaccine, or more than 400 ml of blood was collected within 3 months
  • 15. Persons consuming excessive alcohol or cigarettes
  • 16. Persons with a positive reaction on drug abuse screening
  • 17. Others who are not considered to be eligible by the chief principal investigator or sub-investigator

研究者

发起方
The Research Foundation for Microbial Diseases of Osaka University (BIKEN) (Japan)

相似试验